S8 Ep10: Beyond the Scan: Predicting Immunotherapy Response With ctDNA in NSCLC
Valsamo “Elsa” Anagnostou, MD, PhD, of Johns Hopkins University School of Medicine, joins Targeted Talks to discuss a study on landmark circulating tumor DNA (ctDNA) molecular response in patients with metastatic non–small cell lung cancer (NSCLC) treated with immunotherapy.
Radiographic imaging, the current gold standard, can be slow and imprecise at capturing immunotherapy response. Anagnostou explains why a rapid molecular readout is needed to tailor treatment. In the prospective study of 109 patients, undetectable ctDNA 3 to 9 weeks after starting anti–PD-(L)1 therapy, alone or in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.